CXCL10 and cancer: As proof, in BRCA-mutant cancer cells engrafted in mice models, the activation of STING was linked with a series of immunological changes after olaparib administration: CD3+, CD4+, and CD8+ T-cells, NK cells, and circulating levels of pro-inflammatory cytokines such as IFN, CCL5, and C-X-C motif chemokine ligand 10 (CXCL10) increased [74].